This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Evaluation of Point-of-Care (EPOC) for COVID-19 (NCT05227404), a registered phase not stated study. The primary outcome is Test Results Comparison Between LumiraDx and GenScript.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05227404 |
| Phase | Phase not stated |
| Condition | COVID-19, SARS CoV 2 Infection |
| Allocation | Not Stated |
| Design model | Not Stated |
| Masking | Not Stated |
| Enrollment | 330 |
| Arms in the primary outcome | n/a |
| Lead sponsor | University of Minnesota |
| Results posted | Yes |
2. Clinical Question
Population
The study enrolled 330 participants under the conditions COVID-19 and SARS CoV 2 Infection. The exact eligibility criteria and the participants’ infection or antibody status are not reported in the registry record.
Intervention
Participants received two point-of-care antibody assays: the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test. The study was designed to examine whether these tests could be conducted and how their results compared with a central laboratory assay.
Comparator
The primary comparison is between the LumiraDx test and the GenScript central laboratory assay. The record says all participants received two point-of-care assays and one central laboratory assay, with specimens obtained from the same participants at the same time. RightSign valid-test frequency is listed as a secondary outcome, not as the primary comparator.
Primary question
How different were the proportions of positive results from LumiraDx and GenScript? The primary measure is the difference between those proportions, with a 95% confidence interval. The registry record does not report the observed proportions, their difference, or the confidence interval, so it does not provide an answer to the comparison question.
3. Trial Design
The Evaluation of Point-of-Care (EPOC) for COVID-19 study is a completed diagnostic-test study sponsored by the University of Minnesota. Its official title describes an evaluation of the feasibility and reproducibility of two point-of-care tests for SARS-CoV-2 antibodies. The record gives a start date of 2022-04-08 and a primary completion date of 2022-09-02.
The study enrolled 330 participants. Its brief description says the two point-of-care tests were compared with tests run at a central laboratory on specimens from the same participants at the same time. The arm description states that all participants enrolled would receive two point-of-care assays and one central laboratory assay. This is a within-participant testing arrangement as described in the record; it is not a randomized comparison of separate treatment groups.
The record does not state how participants were allocated, and it flags that allocation was not stated and the arms are not a like-for-like control comparison. It lists LumiraDX, RightSign, and Case Control as diagnostic-test interventions, but does not explain the role of the Case Control entry. The precise assay procedures, specimen handling details, eligibility criteria, and study setting are not reported in the registry record.
The stated purpose is to examine feasibility and compare results across tests. The listed secondary outcomes concern the frequency of valid LumiraDx and RightSign tests. The registry record reports four outcome measures, but records no analyses. It does not describe a prespecified statistical analysis plan, a sample-size justification for the study, or how the recorded enrollment relates to any planned target.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | COVID19 Assays |
|---|---|
| STARTED | 330 |
| COMPLETED | 330 |
| NOT COMPLETED | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | COVID19 Assays |
|---|---|---|
| Participants analysed | 330 | |
| Age, Categorical: <=18 years | Participants | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 148 |
| Age, Categorical: >=65 years | Participants | 182 |
| Sex: Female, Male: Female | Participants | 153 |
| Sex: Female, Male: Male | Participants | 177 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 2 |
| Race (NIH/OMB): Asian | Participants | 21 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 |
| Race (NIH/OMB): Black or African American | Participants | 62 |
| Race (NIH/OMB): White | Participants | 221 |
| Race (NIH/OMB): More than one race | Participants | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 24 |
6. Primary Endpoint
The registry lists the primary outcome as Test Results Comparison Between LumiraDx and GenScript, measured over an average of 1 day.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | 95% Confidence Interval |
| Unit | Unitless |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is titled “Test Results Comparison Between LumiraDx and GenScript.” It measures the difference between the proportions of positive results from the point-of-care LumiraDx test and the GenScript assay. The unit is described as unitless, because the measure is a difference between proportions rather than a measurement on a physical scale. The registry record gives a 95% confidence interval as the dispersion measure and an average timeframe of 1 day.
This endpoint is used to quantify how closely the tests agree in the frequency of positive results. Comparing proportions can show whether one test produces positive results more or less often than the other in the tested participants. However, a difference in positive proportions does not show whether the same individuals tested positive on both assays. Assessing that pattern would require paired-result information, which is not reported in the registry record.
The record does not specify the direction used to subtract one proportion from the other. It also does not report the two proportions, their difference, or the confidence interval. As a result, neither the magnitude nor the precision of the primary comparison can be described from the registry results.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies a quantitative primary endpoint, but it does not report the observed endpoint value. It therefore does not establish whether the positive-result proportions were similar or different, how large any difference was, or how uncertain the estimate was. The record’s completion status and enrollment count do not substitute for an outcome estimate.
The endpoint is a difference between proportions positive for LumiraDx and GenScript. If reported, its sign and size would need to be interpreted using the subtraction order and the proportions themselves. The registry record does not state the subtraction convention or provide those values. It would therefore be inappropriate to describe which test had the higher positive-result proportion, or to characterize the extent of agreement.
A 95% confidence interval would describe the statistical uncertainty around the estimated difference under the method used to calculate it. In general, a narrower interval indicates greater precision, while a wider interval indicates less precision. The interval’s position relative to zero can help assess whether the data are compatible with no difference under the chosen analysis, but it is not a measure of clinical importance. No interval is reported in the registry record, and the method used to calculate one is not reported either.
The study description says that tests were performed on specimens from the same participants at the same time. That arrangement can support a paired comparison, because each participant contributes results from multiple assays. General statistical principle: analyses that account for pairing can use the within-participant relationship between results; treating measurements as independent can fail to reflect that relationship. The registry record does not state whether the primary comparison used a paired method or how participant-level paired results were handled.
The study’s stated aims include feasibility and reproducibility. The primary endpoint, as described, compares the proportions of positive results. It does not by itself report test completion, invalid results, or the full pattern of agreement for individual participants. The secondary outcomes name valid-test frequencies for LumiraDx and RightSign, but their observed values are not reported. No analyses are recorded, so the posted results do not offer an inferential account of those outcomes.
The record reports 330 enrolled participants and a completed study, but does not provide an analysis population or the number of participants contributing to each endpoint. Without those details and the missing estimates, the extent to which the endpoint reflects all enrolled participants cannot be determined. The available record supports describing the planned comparison and its intended measure, not drawing a conclusion about the tests’ comparative results.
9. Statistical Methods Explained
The primary measure is a difference between two proportions: the proportion of positive results from LumiraDx and the proportion of positive results from GenScript. A proportion represents the share of tested observations classified as positive. A difference in proportions expresses the contrast on the proportion scale. The endpoint is described as unitless because it is not a physical measurement such as time or concentration.
What does the comparison measure?
In general, comparing positive-result proportions addresses whether the assays produce positive results at similar frequencies in the participants tested. This summary does not capture every aspect of agreement. For example, two tests could have similar overall positive proportions while classifying some individual participants differently. To describe participant-level agreement, one would need the paired result pattern, including how often both tests were positive, both were negative, or they disagreed. Those counts and any agreement statistic are not reported in the registry record.
The study description says specimens from the same participants were assessed with point-of-care and central laboratory tests at the same time. This makes the observations potentially paired: each participant can contribute a result to more than one assay. General statistical principle: paired data contain a within-participant relationship, and an analysis can use that relationship rather than treating every assay result as unrelated. The registry record does not state whether the primary endpoint was analyzed with a paired procedure, how missing or discordant results were treated, or what calculation was used for the confidence interval.
What does the confidence interval contribute?
The registry identifies a 95% confidence interval as the measure of dispersion for the primary endpoint. In general, a confidence interval presents a range of values compatible with the data and the calculation method, reflecting sampling uncertainty. It helps readers judge the precision of an estimate; it does not mean that there is a 95% probability that a particular fixed interval contains the true value. The actual interval is not reported in the registry record, and the statistical method used to construct it is not reported either.
For a difference in proportions, the interval’s location and width would matter alongside the point estimate. An interval concentrated near zero would tell a different story about the range of plausible differences than one extending across a broad range. This is a general explanation, not a description of the EPOC results: no point estimate or interval is available in the registry record. The record also does not provide a decision threshold for interpreting the size of a difference.
What can valid-test frequencies show?
The listed secondary outcomes are LumiraDx Valid Test Frequency and RightSign Valid Test Frequency. In general, a valid-test frequency can describe how often an assay yields a result that meets the study’s validity criteria. This addresses an operational aspect of testing and is distinct from whether a result is positive or negative. The registry record does not define the validity criteria or report either frequency, so their values and precision cannot be assessed.
The record gives four outcome measures but records no analyses. It does not state whether outcomes were summarized descriptively, whether formal hypothesis tests were performed, or how uncertainty was calculated for the secondary outcomes. It also does not identify an analysis population or explain how participants without a valid result would be handled.
How should planning illustrations be read?
Any planning illustrations based on the observed effect are not evidence of the study’s actual design or an estimate of its achieved power. The stated illustration assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. These are planning assumptions, not a reported protocol justification. The record says allocation was not stated and cautions that the arms are not a like-for-like control comparison. It does not report the original sample-size justification or an observed-effect value in the results.
General statistical principle: over-dispersion matters when variation in count data exceeds what a chosen model expects. If a count outcome is over-dispersed, a model that assumes less variation can give uncertainty estimates that are too small. The primary endpoint is a difference in proportions, and the registry record does not report a count model or an over-dispersion assessment. This general concept should not be mistaken for a method used in this study.
10. Multiplicity, Missing Data and Analysis Populations
The registry record lists four outcome measures, including the primary comparison of LumiraDx with GenScript and secondary outcomes for valid LumiraDx and RightSign tests. It records no analyses. No multiplicity strategy is reported in the registry record, including whether the primary endpoint was treated as the sole confirmatory question or whether any adjustment was planned across outcomes.
General statistical principle: when several outcomes or hypotheses are tested, the chance of obtaining at least one apparently unusual result can increase. A prespecified approach to multiplicity helps readers understand how multiple questions were handled. Because no analysis is recorded, the registry does not show whether any formal tests were performed or how multiple comparisons, if any, were addressed.
Missing-data methods are not reported in the registry record. The record does not state how missing assay results, invalid tests, or participants lacking results from one of the assays were handled. It does not report the number of missing observations for the primary comparison or either secondary outcome.
The analysis population is also not reported. Although enrollment was 330, the record does not say how many participants contributed to each outcome or whether all enrolled participants were included in an analysis. It does not describe exclusions, protocol deviations, or the handling of repeat tests. These omissions prevent assessment of whether the reported endpoint, if available, would reflect all enrolled participants or a selected subset.
11. What the Result Does, and Does Not, Mean
The record describes a completed study of two point-of-care antibody tests and a central laboratory assay, with the primary measure defined as the difference in positive-result proportions for LumiraDx and GenScript. It does not report that difference, the component proportions, the confidence interval, or an analysis. Consequently, the registry record does not establish the direction, size, or precision of the primary comparison.
The endpoint would address the relative frequency of positive results, not every feature of assay agreement. Even a reported difference in proportions would not, by itself, show how often the two tests gave matching results for the same participant. Participant-level agreement information is not reported in the registry record. The listed valid-test-frequency outcomes would address a separate operational question, but their results are not reported either.
The study’s stated aim includes feasibility and reproducibility. The record identifies those aims but does not provide outcome data that allow their assessment. It is therefore not possible to infer from the registry results how frequently either point-of-care test produced a valid result or how reproducible its results were.
These limitations concern what can be concluded from the registry record, not what may exist in other study materials. No conclusion about clinical performance, diagnostic accuracy, or usefulness follows from a study description alone. The available information supports a description of the design and intended comparison; it does not support a claim that either test performed better or worse.
General statistical principle: an estimate and its uncertainty are both important. A point estimate without precision information can be difficult to interpret, while an uncertainty interval without an estimate cannot characterize the observed contrast. Neither is reported for the primary endpoint in this record.
12. Why This Trial Matters Statistically
This study raises a useful statistical distinction between comparing test-result frequencies and assessing agreement. The primary endpoint compares the proportions of positive results from LumiraDx and GenScript. That summary can describe a difference in overall positive frequency, but it does not reveal whether the assays gave the same result for each participant. Because the study description says the same participants were tested, paired-result information would be relevant to a fuller account of agreement.
The study also places operational feasibility alongside result comparison. Valid-test frequency is listed for both point-of-care assays as a secondary outcome. In general, the ability to obtain a valid result and the agreement of results among assays are different questions and require different summaries. The registry record gives the outcome names but not their definitions or observed values.
For statistical interpretation, the missing estimates are decisive. A completed study and an enrollment count do not show the magnitude or precision of an assay comparison. The record identifies a 95% confidence interval for the primary measure but does not report it, and it records no analyses. Readers therefore cannot evaluate the observed contrast or its uncertainty using the registry record.
The record also cautions against treating the study entries as a randomized, like-for-like control comparison. That distinction matters because the design described is testing multiple assays in participants, not assigning different groups to competing interventions. Clear separation of the paired diagnostic question, the operational outcomes, and any planning assumptions is essential to interpreting what the study can address.
13. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The central limitation is that the registry record does not report the primary endpoint result or any analyses. It gives no positive-result proportions, difference, confidence interval, or analysis method. Without these, the comparative result and its precision cannot be evaluated.
Although the study description says tests were performed on specimens from the same participants at the same time, the record does not provide paired-result data or state how pairing was handled analytically. The endpoint compares positive proportions, which does not alone describe participant-level agreement. The record also does not state the subtraction order for the difference.
Details needed to assess test conduct and the analysis population are not reported in the registry record. These include eligibility criteria, assay validity criteria, missing-result handling, the number of participants contributing to each outcome, and the method for calculating the confidence interval. The record does not report the study’s original sample-size justification or a prespecified statistical plan.
The record lists a Case Control diagnostic-test intervention but does not explain its role. It also says allocation was not stated and cautions that the arms are not a like-for-like control comparison. This limits interpretation of the listed interventions as comparative groups.
Finally, the adverse-event fields list 0 for event counts and 0 for participants in the at-risk fields. With no participants recorded in those at-risk fields, these entries do not establish that adverse events were absent among the enrolled participants. The registry record does not provide further safety analysis.
14. Related Tutorials
15. Related Statistical Calculators
16. Sources
- ClinicalTrials.gov: Evaluation of Point-of-Care (EPOC) for COVID-19 — NCT05227404.
- Registry record last updated 2024-12-06; status last verified 2024-12.
- Results first posted 2024-12-06.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
17. Record Summary
NCT05227404, titled “Evaluation of Point-of-Care (EPOC) for COVID-19,” is a completed study sponsored by the University of Minnesota. Its official title describes evaluating the feasibility and reproducibility of two point-of-care tests for SARS-CoV-2 antibodies. The record lists 330 enrolled participants, a start date of 2022-04-08, and a primary completion date of 2022-09-02.
The study description says all participants received two point-of-care assays and one central laboratory assay. Its primary measure compares the proportions of positive results from LumiraDx and GenScript and specifies a 95% confidence interval. Secondary outcomes concern valid-test frequencies for LumiraDx and RightSign.
The primary result, secondary results, and statistical analyses are not reported in the registry record. The record also does not report the analysis population, missing-data methods, or a statistical analysis plan.